NCT06055153 is a Phase 1, PHASE2 clinical trial of RC48+PD-1+platinum-based in Esophageal Squamous Carcinoma, sponsored by Changhai Hospital.

Who is sponsoring NCT06055153?

NCT06055153 is sponsored by Changhai Hospital.

What drugs are being tested in NCT06055153?

Interventions in NCT06055153: RC48+PD-1+platinum-based.

What condition does NCT06055153 study?

NCT06055153 studies Esophageal Squamous Carcinoma, HER-2 Protein Overexpression.

Is NCT06055153 still recruiting?

NCT06055153 is currently status unknown. Last updated 26 September 2023.

Last reviewed 2023-09-26 · How we verify

NCT06055153

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

Status unknown Phase 1, PHASE2 Last updated 26 September 2023

What this trial tests

Phase 1, PHASE2 trial testing RC48+PD-1+platinum-based in Esophageal Squamous Carcinoma in 20 participants. Status unknown.

Timeline

30 September 2023

Primary endpoint
28 February 2025

30 April 2025

Quick facts

Lead sponsor	Changhai Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	30 September 2023
Primary completion	28 February 2025
Estimated completion	30 April 2025

Drugs / interventions tested

RC48+PD-1+platinum-based — full drug profile →

Conditions studied

Esophageal Squamous Carcinoma — all drugs for Esophageal Squamous Carcinoma →
HER-2 Protein Overexpression — all drugs for HER-2 Protein Overexpression →

Sponsor

Changhai Hospital

Who can join

18 and older, any sex, with Esophageal Squamous Carcinoma or HER-2 Protein Overexpression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, exploratory clinical study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06055153 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06055153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing